{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:16:59Z","timestamp":1787314619343,"version":"build-2736575974"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Ibrutinib is a first\u2010in\u2010class oral covalent inhibitor of Bruton's tyrosine kinase that has demonstrated clinical benefit for many patients with B cell malignancies. Positive results in initial trials led the U.S. Food and Drug Administration to grant ibrutinib three breakthrough therapy designations for mantle cell lymphoma (MCL), del17p chronic lymphocytic leukemia (CLL), and Waldenstr\u00f6m's macroglobulinemia (WM). Ibrutinib was approved for these three cancers within 14 months of the original U.S. approval. Additionally, ibrutinib is approved for patient subsets with MCL and\/or CLL in &gt;45 other countries. Via a unique mechanism of action, ibrutinib inhibits B cell signaling pathways that regulate the survival, proliferation, adhesion, and homing of cancerous cells. This marks a paradigm shift from the conventional cytotoxic chemotherapy approach to treating B cell malignancies. Ibrutinib continues to be evaluated across a range of B cell malignancies, either as single\u2010agent therapy or in combination with other therapies, and continues to transform the lives of these patients.<\/jats:p>","DOI":"10.1111\/nyas.12878","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T09:07:35Z","timestamp":1441703255000},"page":"82-94","source":"Crossref","is-referenced-by-count":40,"title":["Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies"],"prefix":"10.1111","volume":"1358","author":[{"given":"Urte","family":"Gayko","sequence":"first","affiliation":[{"name":"Pharmacyclics, Inc  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mann","family":"Fung","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong","family":"Clow","sequence":"additional","affiliation":[{"name":"Pharmacyclics, Inc  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sun","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Faust","sequence":"additional","affiliation":[{"name":"Pharmacyclics, Inc  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiyeh","family":"Price","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle","family":"James","sequence":"additional","affiliation":[{"name":"Pharmacyclics, Inc  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Bari","sequence":"additional","affiliation":[{"name":"Pharmacyclics, Inc  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen Hong","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589"},{"key":"e_1_2_8_4_1","first-page":"530","volume-title":"Postgraduate Haematology","author":"Catovsky D.","year":"2011"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.010"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12046"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23176"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.05.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr377"},{"key":"e_1_2_8_10_1","unstructured":"National Comprehensive Cancer Network.2015.NCCN non\u2010Hodgkin lymphoma guidelines 2015. Accessed February 3 2015.http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nhl.pdf."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.03.009"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/asheducation.V2012.1.586.3798562","article-title":"Are you sure this is Waldenstrom macroglobulinemia?","volume":"2012","author":"Ghobrial I.M.","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3937"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200490"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/28962"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664797"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.777837"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-012-0147-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.803226"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.57"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1182\/blood.V124.21.4453.4453","article-title":"Single\u2010agent ibrutinib demonstrates safety and durability of response at 2 years follow\u2010up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open\u2010label phase 2 study","volume":"124","author":"Wang M.L.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"e_1_2_8_38_1","unstructured":"IMBRUVICA [prescribing information].2015.www.janssenmd.com\/pdf\/imbruvica\/PI\u2010Imbruvica.pdf. Accessed August 25 2015."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V124.21.22.22","article-title":"22 complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib\u2010based regimens","volume":"124","author":"Thompson P.A.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8659"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.039"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-439307"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23620"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7920"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-338558"},{"key":"e_1_2_8_50_1","unstructured":"IMBRUVICA [summary of product characteristics].2015.www.medicines.org.uk\/emc\/medicine\/29383. Accessed August 25 2015."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2762"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-8051-8_2"},{"key":"e_1_2_8_53_1","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood.V124.21.4696.4696","article-title":"Hematologic and immunologic function and patient well\u2010being for the phase III RESONATETM study of ibrutinib vs ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"124","author":"Barrientos J.","year":"2014","journal-title":"Blood"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.12878","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nyas.12878","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T18:24:44Z","timestamp":1695666284000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.12878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,8]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/nyas.12878"],"URL":"https:\/\/doi.org\/10.1111\/nyas.12878","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,8]]}}}